Evantigen, Inc invents, develops, and manufactures uniquely engineered extracellular vesicles (EVs) that express critical membrane protein antigens at very high densities for vaccines and immune tolerance therapeutics. These vesicles are engineered via Evantigen’s proprietary WAEV™ Platform which has a low-cost and facile manufacturability with durable temperature-stable storage.
We are committed to advancing vaccine-based EVs and seek collaborations and partnerships with others in the EV, vaccine, and autoimmunity fields to create the synergy necessary to deliver effective products that combat infectious diseases and autoimmune conditions.
For more information about partnering/collaborating with Evantigen, contact David Alleva, PhD via dalleva@evantigen.com
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Evantigen, Inc. Questions
Evantigen, Inc.'s LinkedIn profile is https://www.linkedin.com/company/evantigen-inc
Evantigen, Inc.'s industry is
Biotechnology Research
Evantigen, Inc.'s top competitors are
Morningside,
Neutrolis Inc,
Innodem Neurosciences,
Fount Bio, Inc.,
Pacdna Inc.,
Firecyte Therapeutics,
Cyted Health,
Valitor,
I2o Therapeutics,
Biothea Pharma Inc..
Evantigen, Inc.'s categories are Biotechnology Research
Evantigen, Inc.'s founding year is 2022
